| Texto completo | |
| Autor(es): Mostrar menos - |
Proto-Siqueira‚ R.
;
Figueiredo-Pontes‚ L.L.
;
Panepucci‚ R.A.
;
Garcia‚ A.B.
;
Rizzatti‚ E.G.
;
Nascimento‚ F.M.
;
Ishikawa‚ H.C.F.
;
Larson‚ R.E.
;
Falcão‚ R.P.
;
Simpson‚ A.J.
;
others
Número total de Autores: 11
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Leukemia Research; v. 30, n. 11, p. 1333-1339, 2006. |
| Resumo | |
The preferentially expressed antigen in melanoma (PRAME) gene is aberrantly expressed in chronic lymphoproliferative disorders (CLD). We produced and characterized an anti-PRAME monoclonal antibody (MoAb), which was then applied in a quantitative flow cytometric (QFC) method to evaluate PRAME expression in leukemic cells from the peripheral blood (PB) of 47 patients with chronic lymphocytic leukemia and seven with mantle cell lymphoma as well as in the PB mononuclear cells (PBMCs) and B lymphocytes from 15 healthy subjects. Approximately 90% of CLD, but none of the normal samples, presented more than 20% of PRAME+ lymphocytes. Moreover, the intensity of PRAME expression was significantly higher in CLD cells compared to normal B lymphocytes and PBMCs. By immunofluorescence microscopy and by permeabilized flow cytometry we demonstrated that PRAME is a membrane antigen and a cytoplasmic protein aberrantly expressed in malignant CLD. Our results suggest that the analysis of PRAME protein may contribute for the distinction between normal and leukemic cells in CLD, and that PRAME may be a potential target for therapy. (c) 2006 Elsevier Ltd. All rights reserved. (AU) | |
| Processo FAPESP: | 98/14247-6 - Center for Research on Cell-Based Therapy |
| Beneficiário: | Marco Antonio Zago |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |